 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the company plans to participate at the following conferences in February 2021: CAR-TCR Digital Summit Europe Date: Wednesday, February 17, 2021 Time: 2:00 p.m. GMT 3 p.m. CET SVB Leerink Partners Global Healthcare Co 